reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
08-09-2010

New data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing.

Read more
reMYND and Amorfix announce agreement
06-07-2010
Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement.
Read more
Ablynx and reMYND settle dispute amicably
02-06-2010
Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement.
Read more
reMYND receives a grant of 0.9 million EUR from IWT
10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND receives license renewal from Schering-Plough for RadarScreen
18-11-2009
reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough.
Read more
reMYND receives award for Company with an exceptional relevance to society
21-09-2009
reMYND received 'the 1st Award for Company with an exceptional relevance to society'.
Read more
reMYND awarded by the Michael J. Fox Foundation
21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation
Read more
reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND installs world-class scientific advisory board
25-06-2008
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.
Read more